Startup HiberCell gets more than $60M to focus on mechanism behind cancer metastasis, recurrence
The New York-based company has two programs in preclinical discovery, based on research conducted at Mount Sinai's Tisch Cancer Institute.
Polaris Partners launches Dewpoint Therapeutics with $60M round
The company will focus on what it called a previously unexplored field in drug discovery, membrane-less cell organelles called biomolecular condensates
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Fulcrum Therapeutics raises $80M to develop muscular dystrophy drug
Estimates of the incidence of FSHD, which has two types, range from 1-in-20,000 to 1-in-8,333, or about 870,000 cases worldwide.